Opna Bio is targeting key regulators to advance the treatment of cancer. OPN-6602, a best-in-class EP300 inhibitor, is currently in clinical development for treatment of patients with multiple myeloma. Zavabresib, a differentiated BET inhibitor, is being developed for the treatment of myelofibrosis.
EXPLORE OUR PIPELINE
Opna Bio is dedicated to discovering and developing novel treatments for cancer patients everywhere.
We are currently validating our approach of competitive safety and efficacy through differentiated PK with our epigenetic inhibitors, OPN-6602 and zavabresib. Both compounds are currently in early-stage clinical development in patients with hematologic malignancies.
Explore our Clinical TrialsSOUTH SAN FRANCISCO, CA – January 21, 2026 – Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and […]
Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH)
Phase 1 Clinical Trial with OPN-6602 in Multiple Myeloma Actively Enrolling Patients